» Articles » PMID: 32766303

Secondary Metabolites of Leaf Extract Induce Apoptosis in Breast, Liver, and Colon Cancer Cells by Caspase-3-Dependent Intrinsic Pathway

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2020 Aug 9
PMID 32766303
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Apoptosis, a major form of programmed cell death, plays a vital role in regulating tissue development and maintenance of homeostasis in eukaryotes. Apoptosis can occur via a death receptor-dependent extrinsic or a mitochondrial-dependent intrinsic pathway and can be induced by various chemotherapeutic agents. In this study, the anticancer activity of and its mode of intervention in human cancer cells of breast, colon, and liver were investigated.

Results: In this study, the bioactives of leaves were extensively extracted in five solvents of different polarity. The cytotoxicity and anticancer effect of the extracted secondary metabolites were investigated against breast (MCF-7), liver (HepG2), and colon (HCT116) cancer cell lines using a Sulphorhodamine B (SRB) assay. Secondary metabolites extracted using hexane, methanol, ethyl acetate, and chloroform had the highest cytotoxicity and thus the greatest anticancer effect on all the cancer cell lines tested (IC; ranging from 0.25 to 2.5 g/ml), while butanol was comparatively less active (IC; ranging from 23.2 to 25.5 g/ml). Further investigation using DNA flow cytometry and fluorescent microscopy revealed that the extract arrested the cells in the G phase of cell cycle and induced apoptosis. Furthermore, the elevated expression level of proapoptotic proteins and decreased expression level of antiapoptotic proteins confirmed that the intrinsic (mitochondrial) pathway was involved in mediating the apoptosis of cancer cells upon treatment with extract. These results altogether suggest that could be a potential anticancer agent.

Conclusion: These results suggest that the extract is the potential source of the secondary metabolites that could be used as anticancer agent to treat diverse cancers of breast, colon, and liver.

Citing Articles

Ethnobotanical survey of medicinal plants used in management of breast cancers in Qatar.

El Alaa R, Al-Jaber H, Chokor F, Shaito A, Al-Mansoori L Heliyon. 2025; 11(4):e42541.

PMID: 40028611 PMC: 11869100. DOI: 10.1016/j.heliyon.2025.e42541.


Current and potential future biological uses of (Falc.) Lipsch: A comprehensive review.

Elnour A, Abdurahman N Heliyon. 2024; 10(18):e37790.

PMID: 39323795 PMC: 11422592. DOI: 10.1016/j.heliyon.2024.e37790.


Antimycobacterial and Anticancer Properties of Leaf Extract.

Mir M, Memish L, Elbehairi S, Bashir N, Masoud F, Shati A Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065723 PMC: 11279575. DOI: 10.3390/ph17070872.


HPLC-PDA Method for Quantification of Bioactive Compounds in Crude Extract and Fractions of Falc. and Cytotoxicity Studies against Cancer Cells.

Bhushan A, Rani D, Tabassum M, Kumar S, Gupta P, Gairola S Molecules. 2023; 28(12).

PMID: 37375368 PMC: 10303526. DOI: 10.3390/molecules28124815.


Comparison of the Anti-bacterial Efficacy of and Against , and : An Study.

BinShabaib M, ALHarthi S, Helaby B, AlHefdhi M, Mohammed A, Aabed K Front Oral Health. 2022; 3:950840.

PMID: 35833191 PMC: 9271692. DOI: 10.3389/froh.2022.950840.


References
1.
Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

2.
Forner A, Llovet J, Bruix J . Hepatocellular carcinoma. Lancet. 2012; 379(9822):1245-55. DOI: 10.1016/S0140-6736(11)61347-0. View

3.
Ly J, Grubb D, Lawen A . The mitochondrial membrane potential (deltapsi(m)) in apoptosis; an update. Apoptosis. 2003; 8(2):115-28. DOI: 10.1023/a:1022945107762. View

4.
Pandey M, Govindarajan R, Rawat A, Pushpangadan P . Free radical scavenging potential of Saussarea costus. Acta Pharm. 2005; 55(3):297-304. View

5.
Rajagopalan P, Alahmari K, Elbessoumy A, Balasubramaniam M, Suresh R, Ahmed Shariff M . Biological evaluation of 2-arylidene-4, 7-dimethyl indan-1-one (FXY-1): a novel Akt inhibitor with potent activity in lung cancer. Cancer Chemother Pharmacol. 2016; 77(2):393-404. DOI: 10.1007/s00280-015-2956-8. View